DHS Supports FDA Authorization, CDC Recommendation for Pfizer COVID-19 Vaccine Booster Dose for 16- and 17-year-olds
The Wisconsin Department of Health Services (DHS) supports the recommendation that 16- and 17-year-olds receive a booster dose of the Pfizer-BioNTech COVID-19 vaccine at least six months after having received their second dose of the Pfizer-BioNTech (Pfizer) COVID-19 vaccine.
After rigorous review of all available data, the Food and Drug Administration (FDA) authorized and the Centers for Disease Control and Prevention's (CDC) Director recommended 16- and 17-year-olds receive a booster dose of the Pfizer-BioNTech COVID-19 vaccine.
With this recommendation combined with earlier recommendations, DHS and CDC now recommend a COVID-19 vaccine booster dose for everyone 16 and older. View the updated CDC COVID-19 Booster Shots webpage here.
DHS recommends:
People between 16 and 17 years of age can receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their second dose of the Pfizer-BioNTech COVID-19 vaccine.
Updated Clinical Considerations
The updated CDC Interim Clinical Considerations have been published.
After ensuring all clinical requirements are met, vaccinators should accept verbal self-attestation as sufficient proof for the administration of a booster dose. The Wisconsin Department of Health Services (DHS) will not supply an attestation form to vaccinators and does not recommend the use of written attestation forms.
Updated Emergency Use Authorizations
Administration
All vaccinators are now able to begin providing boosters to this population immediately. The Immunization Program's Policy and Procedure Manual has been updated.
Primary Series Vaccination
We urge you to continue conversations with folks who are not yet vaccinated. While booster doses are an important step in increasing access to enhanced protection for people across Wisconsin, there remains large populations of people who are unvaccinated and who are at risk of serious illness and death.
We need a strong continued focus on increasing primary vaccination among these individuals. You can find a number of resources to support these conversations on the DHS COVID-19 Vaccine Partner and Vaccinator Resources webpage.
|
